Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by JMP Securities

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a report released on Monday, Benzinga reports. They currently have a $12.00 target price on the stock. JMP Securities’ price objective indicates a potential upside of 109.79% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Monday.

Werewolf Therapeutics Stock Down 4.3 %

NASDAQ HOWL opened at $5.72 on Monday. The stock has a fifty day moving average of $6.18 and a 200-day moving average of $4.70. The stock has a market capitalization of $247.96 million, a P/E ratio of -5.25 and a beta of 0.71. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.10. Werewolf Therapeutics had a negative return on equity of 36.43% and a negative net margin of 256.33%. The company had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.75 million. On average, equities research analysts forecast that Werewolf Therapeutics will post -1.38 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Certuity LLC acquired a new position in Werewolf Therapeutics in the fourth quarter valued at about $39,000. Financial Perspectives Inc boosted its stake in shares of Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after buying an additional 3,000 shares during the last quarter. Denali Advisors LLC bought a new position in shares of Werewolf Therapeutics in the 1st quarter valued at about $172,000. PFM Health Sciences LP increased its position in shares of Werewolf Therapeutics by 35.6% in the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after acquiring an additional 909,895 shares during the last quarter. Finally, Lighthouse Investment Partners LLC bought a new stake in Werewolf Therapeutics during the fourth quarter worth about $87,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.